Three drugmakers, including Ranbaxy Laboratories of India, won the first approvals to sell copies of GlaxoSmithKline's AZT, or Retrovir, in the U.S. Other firms cleared to produce generic copies of AZT, first approved by the FDA 18 years ago, include Aurobindo Pharma of India and Roxane Laboratories, a U.S. unit of Germany's Boehringer Ingelheim.

Full Story:

Related Summaries